ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3024% above fair value
$1409.38−1.61 (-0.11%)
Close on Nov 3, 2026Market cap $1.33TP/E 45.7Yield 0.44%
Eli Lilly Trulicity by Quarter
Trulicity — Worldwide revenue ($M) [Q1–Q3 10-Q & FY through FY2024] ($M)
Eli Lilly Trulicity: $1,219M in Q2 2026, up 11.6% from a year earlier.
Latest, Q2 2026
1,219
Period ended Jun 30, 2026
Change on a year earlier
+11.6%
1,092 in Q2 2025
History
37 quarters
Since Q1 2017
Sources
33
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q MD&A & Form 10-K through FY2024.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Eli Lilly Trulicity ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-trulicity-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.
See a number that looks wrong?